VTGN Reddit Mentions | ChartExchange

SLS hits 80 events. The stock goes up so much that a circuit is triggered.
DRTS presents top-line data from a combo of DaRT and Keytruda on July 21st. Possible abscopal effect rumors along with validation of the combination strategy.
* June 30, 2026 (Tomorrow)
* **AZN**
* **Catalyst Date:** Jun 30, 2026
* **Stage/Event:** PDUFA (Supplemental NDA for Truqap)
* **AZN** *(Separate asset)*
* **Catalyst Date:** Jun 30, 2026
* **Stage/Event:** PDUFA (NDA for camizestrant)
* **MBRX**
* **Catalyst Date:** Jun 30, 2026
* **Stage/Event:** Phase 2b/3 Trial Readout (Annamycin + cytarabine interim data)
* **VRDN**
* **Catalyst Date:** Jun 30, 2026
* **Stage/Event:** PDUFA (BLA for veligrotug)
# July 2026
* **MBRX** *(Separate trial track)*
* **Catalyst Date:** Jul 1, 2026
* **Stage/Event:** Phase 2b/3 Trial Readout (Annamycin interim data)
* **Orca Bio** *(No ticker listed)*
* **Catalyst Date:** Jul 6, 2026
* **Stage/Event:** PDUFA (BLA for Orca-T)
* **VERA**
* **Catalyst Date:** Jul 7, 2026
* **Stage/Event:** PDUFA (BLA for atacicept)
* **SWTX**
* **Catalyst Date:** Jul 10, 2026
* **Stage/Event:** PDUFA (NDA for mirdametinib)
* **CELC**
* **Catalyst Date:** Jul 17, 2026
* **Stage/Event:** PDUFA (NDA for gedatolisib)
* **PTGX**
* **Catalyst Date:** Jul 20, 2026
* **Stage/Event:** Phase 3 Trial Readout (Rusfertide)
* **BIIB**
* **Catalyst Date:** Jul 25, 2026
* **Stage/Event:** PDUFA (Supplemental NDA for Leqembi subcutaneous)
* **NVO**
* **Catalyst Date:** Jul 29, 2026
* **Stage/Event:** PDUFA (BLA for denecimig)
# August 2026
* **IMVT**
* **Catalyst Date:** Aug 15, 2026
* **Stage/Event:** Phase 3 Trial Readout (Batoclimab)
* **PRAX**
* **Catalyst Date:** Aug 17, 2026
* **Stage/Event:** PDUFA (NDA for ulixacaltamide)
* **KALV**
* **Catalyst Date:** Aug 20, 2026
* **Stage/Event:** FDA Advisory Committee (AdCom) Meeting (Donidalorsen)
* **Landos Biopharma** *(No ticker listed)*
* **Catalyst Date:** Aug 20, 2026
* **Stage/Event:** PDUFA (NDA for omilancor)
* **CAPR**
* **Catalyst Date:** Aug 22, 2026
* **Stage/Event:** BLA Submission/PDUFA Target (Deramiocel)
* **PharmaEssentia** *(No ticker listed)*
* **Catalyst Date:** Aug 30, 2026
* **Stage/Event:** PDUFA (Supplemental BLA for BESREMi)
# September 2026 and Beyond
* **AZN**
* **Catalyst Date:** Sep 1, 2026
* **Stage/Event:** Phase 3 Trial Readout (Camizestrant — SERENA-4)
* **BCYC**
* **Catalyst Date:** Sep 1, 2026
* **Stage/Event:** Phase 2 Trial Readout (BT8009)
* **ALNY**
* **Catalyst Date:** Sep 15, 2026
* **Stage/Event:** PDUFA (NDA for zilebesiran)
* **GERN**
* **Catalyst Date:** Sep 15, 2026
* **Stage/Event:** Phase 3 Trial Readout (Rytelo overall survival analysis)
* **PRAX**
* **Catalyst Date:** Sep 27, 2026
* **Stage/Event:** PDUFA (NDA for relutrigine)
* **ROIV**
* **Catalyst Date:** Sep 30, 2026
* **Stage/Event:** PDUFA (NDA for brepocitinib)
* **REGN**
* **Catalyst Date:** Oct 1, 2026
* **Stage/Event:** PDUFA (BLA for pozelimab)
* **KALV**
* **Catalyst Date:** Oct 20, 2026
* **Stage/Event:** PDUFA (NDA for donidalorsen)
* **CYTK**
* **Catalyst Date:** Oct 30, 2026
* **Stage/Event:** PDUFA (Supplemental NDA for MYQORZO)
* **ALNY**
* **Catalyst Date:** Nov 10, 2026
* **Stage/Event:** PDUFA (NDA for elebsiran)
* **VRTX**
* **Catalyst Date:** DEC 5, 2026
* **Stage/Event:** PDUFA (Supplemental NDA for Journavx)

July 2026
* **4568 (Daiichi Sankyo)**
* **Catalyst Date:** Jul 7, 2026
* **Stage/Event:** PDUFA
* **CORT**
* **Catalyst Date:** Jul 11, 2026
* **Stage/Event:** NDA / Regulatory Milestone (Concept)
* **HEL (Elevar Therapeutics)**
* **Catalyst Date:** Jul 23, 2026
* **Stage/Event:** PDUFA
* **SNY**
* **Catalyst Date:** Jul 23, 2026
* **Stage/Event:** PDUFA
* **MNKD**
* **Catalyst Date:** Jul 26, 2026
* **Stage/Event:** Regulatory Milestone
* **VTRS**
* **Catalyst Date:** Jul 30, 2026
* **Stage/Event:** Regulatory Milestone

August 2026
* **MRNA**
* **Catalyst Date:** Aug 5, 2026
* **Stage/Event:** PDUFA
* **LNTH**
* **Catalyst Date:** Aug 13, 2026
* **Stage/Event:** PDUFA
* **BMY**
* **Catalyst Date:** Aug 17, 2026
* **Stage/Event:** PDUFA
* **RARE**
* **Catalyst Date:** Aug 23, 2026
* **Stage/Event:** PDUFA
* **BIIB** *(Eisai / Biogen Joint Program)*
* **Catalyst Date:** Aug 24, 2026
* **Stage/Event:** PDUFA
* **JAZZ**
* **Catalyst Date:** Aug 25, 2026
* **Stage/Event:** PDUFA
* **GILD**
* **Catalyst Date:** Aug 27, 2026
* **Stage/Event:** PDUFA
* **6446 (PharmaEssentia)**
* **Catalyst Date:** Aug 30, 2026
* **Stage/Event:** PDUFA
* **BCYC:** Phase 1/2 Data readout (H1 2026)
* **MBRX:** Phase 3 Data readout (Late Q2 2026)
* **ACIU:** Phase 1/2 Data readout (Q2 2026)
* **VTGN:** Phase 3 Data readout (Q2 2026)
* **GNPX:** Phase 2a Data readout (H1 2026)
* **VXRT:** Phase 2b Data readout (Q2 2026)
* **PASG:** Phase 1/2 Data readout (H1 2026)
* **NVS:** Phase 3 Data readout (Q2 2026)
* **HOWL:** Phase 1/2 Data readout (H1 2026)
* **PBYI:** Phase 2 Data readout (H1 2026)
* **MRKR:** Phase 1 Data readout (Q2 2026)
* **JAGX:** Phase 2 Data readout (June 2026)
* **GLPG:** Phase 2 Data readout (Q2 2026)
* **BINV:** Phase 2a Data readout (Two separate program assets listed for H1 2026)
* **ARGX:** Phase 2 Data readout (H1 2026)
* **CGON:** Phase 3 Data readout (H1 2026)
* **AKRO:** Phase 3 Data readout (Two separate trials listed for H1 2026)
* **PHIO:** Phase 1b Data readout (Q2 2026)
* **CHRS:** Phase 1 Data readout (H1 2026)
* **KTTA:** Phase 1 Data readout (Q2 2026)
* **AQST:** Phase 1 Data readout (Q2 2026)
* **AVDL:** Phase 3 Data readout (Q2 2026)